Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during rumor angiogenesis

Blood

Volumn 96, Issue 2, 2000, Pages 546-553

  Kubo, Hajime ^a   Fujiwara, Takashi ^b   Jussila, Lotta ^b   Hashi, Hiroyuki ^b   Ogawa, Minetaro ^b   Shimizu, Kenji ^b   Awane, Masaaki ^b   Sakai, Yoshiharu ^b   Takabayashi, Arimichi ^b   Alitalo, Kari ^b   Yamaoka, Yoshio ^b   Nishikawa, Shin Ichi ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASCULAR ENDOTHELIUM;

EID: 18544393909     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.2.546.014k12_546_553     Document Type: Article

References (38)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4.
2. Folkman J. Angiogenesis and tumor growth [letter]. N Engl J Med. 1996;334:920.
3. Hanahan D, Folkman J. Parameters and emerging machanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353.
4. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277:48.
5. Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem. 1991;47:219.
6. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996; 380:435.
7. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439.
8. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol. 1995;129:895.
9. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995; 376:70.
10. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87: 1161.
11. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171.
12. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 193; 362:841.
13. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest. 1979; 100:2072.
14. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994; 367:576.
15. Millauer B, Longhi MP, Plate KH, et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 1996; 56:1615.
16. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996;56:4032.
17. Finnerty H, Kelleher K, Morris GE, et al. Molecular cloning of murine FLT and FLT4. Oncogene. 1993;8:2293.
18. Wilting J, Eichmann A, Christ B. The avian VEGF receptor homologues Quek1 and Queck2 during quail embryonic development: expression in blood-vascular and lymphatic endothelial and non-endothelial cells. Cell Tissue Res. 1997;288: 207.
19. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to endothelium of lymphatic vessels during development. Proc Natl Acad Sci U S A. 1995;92:3566.
20. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C is a ligand for Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290.
21. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997;16:3898.
22. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95:548.
23. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasiaof lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276:1423.
24. Oh SJ, Jeltsch MM, Birkenhager R, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol. 1997;188:96.
25. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A. 1998;95:14389.
26. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 1998;282:946.
27. Toda K, Tsujioka K, Maruguchi Y, et al. Establishment and characterization of a tumorigenic murine vascular endothelial cell line (F-2). Cancer Res. 1990;50:5526.
28. Hirashima M, Kataoka H, Nishikawa S, Matsuyoshi N, Nishikawa S-I. Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. Blood. 1999;93:1253.
29. Kataoka H, Takakura N, Nishikawa S, et al. Expression of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. Dev Growth Differ. 1997;39:729.
30. Gasparini G, Harris A. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol. 1995;13:765.
31. Yoshida H, Kunisada T, Kusakabe M, Nishikawa S, Nishikawa SI. Distinct stages of melanocyte differentiation revealed by analysis of nonuniform pigmentation patterns. Development. 1996;122: 1207.
32. Fujiwara T, Uehara Y. The cytoarchitecture of the medial layer in rat thoracic aorta: a scanning electron-microscopic study. Cell Tissue Res. 1992; 270:165.
33. Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K. Signaling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene. 1994;9:3545.
34. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Upregulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 1993; 53:5822.
35. Enholm B, Paavonen K, Ristimaki A, et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene. 1997;22: 2475.
36. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development. 1999;126:1149.
37. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62.
38. Hori K, Suzuki M, Tanda S, Saito S. In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res. 1990;81:279.